Related Experiment Video

Updated: Mar 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Synergistic immunologic targets for the treatment of prostate cancer

Karen M Doersch1, Kelvin A Moses2, Warren E Zimmer3

  • 1Department of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, Temple, TX 76504, USA doersch@medicine.tamhsc.edu.

Experimental Biology and Medicine (Maywood, N.J.)
|July 23, 2016
PubMed

Insights

Targeting interleukin-2 and transforming growth factor-beta in prostate cancer may improve immune response against tumors. This review explores immunologic therapies for prostate cancer, focusing on these key factors.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Prostate cancer remains a leading cause of morbidity and mortality in men.
  • The immune system plays a critical role in prostate cancer pathogenesis and progression.
  • Immunologic therapies offer potential benefits for prostate cancer patients.

Purpose of the Study:

  • To review evidence supporting interleukin-2 and transforming growth factor-beta as therapeutic targets in prostate cancer.
  • To highlight how modulating these factors can enhance anti-tumor immunity.
  • To examine current treatments and their relevance to this immunotherapeutic strategy.

Main Methods:

  • Literature review of studies on prostate cancer immunology.
  • Analysis of the roles of interleukin-2 and transforming growth factor-beta in cancer.
  • Examination of existing therapeutic strategies targeting these factors.

Main Results:

  • Increased interleukin-2 signaling may enhance immune recognition of prostate cancer cells.
  • Decreased transforming growth factor-beta signaling could improve anti-tumor immune responses.
  • Evidence suggests these factors are viable targets for novel prostate cancer treatments.

Conclusions:

  • Modulating interleukin-2 and transforming growth factor-beta presents a promising immunotherapeutic approach for prostate cancer.
  • Further research and clinical trials are warranted to validate these strategies.
  • Targeting immune pathways offers a new avenue for improving outcomes in prostate cancer management.
Keywords:
Prostate cancercombination therapyimmunotherapyinterleukin-2therapeutic targetstransforming growth factor-β

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.2K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K